Suchergebnisse - "Channick, Richard"

PubPharm (13)

1

Effect of Macitentan in Pulmonary Arterial Hypertension and the Relationship Between Echocardiography and cMRI Variables : REPAIR Echocardiography Sub-study Results

enthalten in: Cardiology and therapy | 2024

von Torbicki, A. | Channick, R. | Galiè, N. | +9

2

Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH) : Real-World Evidence from the Combined OPUS/OrPHeUS Dataset

enthalten in: Cardiology and therapy | 2024

von Channick, R. | Chin, K. | McLaughlin, V. | +6

3

Safety of Macitentan for the Treatment of Portopulmonary Hypertension : Real-World Evidence from the Combined OPUS/OrPHeUS Studies

enthalten in: Pulmonary therapy | 2024

von Kim, N. | Chin, K. | McLaughlin, V. | +8

4

Effect of Macitentan in Pulmonary Arterial Hypertension and the Relationship Between Echocardiography and cMRI Variables: REPAIR Echocardiography Sub-study Results

enthalten in: Cardiology and therapy | 2024

von Torbicki, A. | Channick, R. | Galiè, N. | +9

5

Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies

enthalten in: Pulmonary therapy | 2024

von Kim, N. | Chin, K. | McLaughlin, V. | +8

6

Update on Medical Management of Pulmonary Arterial Hypertension

enthalten in: Cardiology clinics | 2022

von Sherman, A. | Saggar, R. | Channick, R.

7

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension : insights from the GRIPHON study

enthalten in: European journal of heart failure | 2022

von Rosenkranz, S. | Channick, R. | Chin, K. | +11

CommentIn: Eur J Heart Fail. 2022 Jan;24(1):215-218. - PMID 34816552

8

Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension : Results from GRIPHON and its Open-Label Extension

enthalten in: Advances in therapy | 2022

von Galiè, N. | Gaine, S. | Channick, R. | +10

9

Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension

enthalten in: Advances in therapy | 2021

von Galiè, N. | Gaine, S. | Channick, R. | +10

10

Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension

enthalten in: Advances in therapy | 2021

von Galiè, N. | Gaine, S. | Channick, R. | +10